What are you looking for?
This Spotlight Series article is editorially independent content. Cataracts are the leading cause of blindness globally and the primary cause of vision loss in the United States. Approximately 20.5 million Americans aged 40 years and older (17.2%) have cataracts in 1 or both eyes, and 6.1 million (5.1%) have undergone lens removal surgery. If left... ...
Patients dissatisfied after presbyopia-correcting intraocular lens (IOL) implantation were most likely to improve with intraocular lens exchange or laser vision correction (LVC),...
William Wiley, MD, of the Cleveland Eye Clinic, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about Atia Vision’s new...
George Waring IV, MD, of the Waring Vision Institute, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about a new...
This Spotlight Series article is editorially independent content. Cataracts are the leading cause of blindness globally and the primary cause of vision loss in the United States. Approximately 20.5 million...
Patients dissatisfied after presbyopia-correcting intraocular lens (IOL) implantation were most likely to improve with intraocular lens exchange or laser vision correction (LVC), according to a study. The analysis included patients...
William Wiley, MD, of the Cleveland Eye Clinic, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about Atia Vision’s new dual optic design intraocular lens for presbyopia. The...
George Waring IV, MD, of the Waring Vision Institute, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about a new feature and design element of presbyopia-correcting intraocular lenses...
TECLens, Inc., announced that the first patient has undergone treatment with its quantitative corneal crosslinking (qCXL™) technology. The first-in-human trial is assessing the safety and efficacy of the CXLens® system...
Case series demonstrates low enhancement rate and high rates of 20/20 and J1 vision The contents of this article are informational only and are not intended to be a substitute...
The U.S. Food and Drug Administration has approved YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults, according to a press release. Formerly known...
AGN-241622 ophthalmic solution was well tolerated in healthy and presbyopic adults and showed modest improvements in near vision, according to results of a Phase 1/2 study. The randomized, vehicle-controlled, participant-...